Trial Profile
A Multi-center, Randomized, Double-blind, Double-dummy, With Olmesartan Medoxomil as Positive Control Parallel Clinical Study to Evaluate the the Safety and Efficacy of Azilsartan in Chinese Patients With Primary Mild and Moderate Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Sep 2018
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Lee's Pharmaceutical
- 30 Aug 2018 Status changed from recruiting to completed.
- 25 Nov 2015 New trial record